medigraphic.com
Colegio de Medicina Interna de México.

2016, Number 3

<< Back Next >>

Med Int Mex 2016; 32 (3)

Quinolones resistance in extended spectrum betalactamase enterobacteriaceae

Salgado-Muñoz TG, Morones-Esquivel I, Gonzaga-López TI, Matamoros-Mejía AP, Terán-González JO, Arteaga-Vázquez S, Castro-D’Franchis LJ, Reyes-Jiménez AE, López-González DS, Meza-Oviedo D

Language: Spanish
References: 25
Page: 277-283
PDF size: 592.98 Kb.


ABSTRACT

Background: Infections caused by extended spectrum beta-lactamase (ESBL) enterobacteriaceae have increased recently, carbapenems are the treatment of choice, but there is evidence of resistance in nosocomial bacterias associated with their abuse. Response to quinolones is reported, in vitro sensitivity has been found; nevertheless, there are records of resistance related with the previous administration of quinolones.
Objetives: To determine the quinolone resistance in ESBL enterobacteriaceae documented in blood and urine isolates at Hospital Central Norte, PEMEX, in 2014, as well as to analyze the correlation with previous administration of quinolones.
Material and Method:A retrospective, observational, descriptive and analytical study was made. Statistical analysis was done with Pearson correlation coefficient and ordinary least squares regression.
Results: 395 isolates with ESBL enterobacteria were included with quinolone resistance of 89% in urine and 90% in blood. Correlation with previous administration of quinolones in blood isolates was of 0.964 and in urine isolates was of 0.940. There is a positive causality between events of 80% in blood isolates and 85% in urine isolates.
Conclusions: We found quinolone resistance in ESBL enterobacteriaceae and statistically significant correlation with the previous administration of quinolones. To reduce this resistance we should make emphasis in antimicrobial-de-escalation based on isolates and education for proper management of quinolones in primary care physicians.


REFERENCES

  1. Bush K, Jacoby GA, Madeiros AA. A functional classification scheme for betalactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-1233.

  2. Sirot D. Extended-spectrum plasmid-mediated β-lactamases. J Antimicrob Chemother 1995;36:19-34.

  3. Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino beta-lactams. Infect Dis Clin North Am 1997;11:875-887.

  4. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-1171.

  5. Gales AC, Sader HS, Jones RN; SENTRY Participants Group (Latin America). Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;44:289-299.

  6. Anton YP, David CH. Hospital-Acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804-1813.

  7. Silva J, et al. Outbreak of infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Mexican hospital. J Clin Microbiol 2001;39:3193-3196.

  8. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-358.

  9. Asensio A, Oliver A, Gonzalez-Diego P, Baquero F, Perez-Díaz JC, et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as a risk factor for colonization and infection. Clin Infect Dis 2000;30:55-60.

  10. Endimiani, A, Luzzaro F, Perilli M, Lobardi G, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004;38:243-251.

  11. Laurent P, Evangelia L, Marisa C, Cindy F, et al. Nosocomial outbreak of extended-spectrum beta-lactamase SHV-5 producing isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrob Agents Chemother 2004;48:2277- 2279.

  12. Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:1847-1851.

  13. Bermejo J y col. Factores de riesgo asociados con las infecciones debidas a Klebsiella pneumoniae resistentes a ceftazidima. Enferm Infecc Microbiol Clin 2003;21:72-76.

  14. Strausbaugh LJ, Crossley KB, Nurse BA, Thrupp LD. Antimicrobial resistance in long-term-care facilities. Infect Control Hosp Epidemiol 1996;17:129-140.

  15. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:72s-75s.

  16. Meyer KS, Urban C, Eagen JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 1993; 119:353-358.

  17. Wiener J, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-523.

  18. Rahal JJ, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998:280:1233-1237.

  19. Urban C, Go E, Mariano N, Berger BJ, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-451.

  20. Karas JA, Pillay DG, Muckart D. Treatment failure due to extended-spectrum β-lactamase. J Antimicrob Chemother 1996;37:203-204.

  21. Lautenbach E, Strom BL, Bilker WB, Patel JB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. CID 2001;33:1288-1294.

  22. Shahcheraghi F, Moezi H, Feizabadi MM. Distribution of TEM and SHV beta-lactamase genes among Klebsiella pneumoniae strains isolated from patients in Tehran. Med Sci Monit 2007;13:247-250.

  23. Tumbarello M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498-504.

  24. Garza-Gonzalez E, Mendoza Ibarra SI, Llaca-Diaz JM, Gonzalez GM. Molecular characterization and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates at a tertiary care centre in Monterrey, Mexico. J Medical Microbiol 2011;60:84-90.

  25. Muro S, et al. Risk factors associated with extendedspectrum- beta-lactamase-producing enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis. Chemotherapy 2012;58:217-224.




2020     |     www.medigraphic.com